En savoir plus
Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models.
The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development.
Table des matières
1. Chronic respiratory diseases: An introduction and need for novel drug delivery approaches 2. Drug delivery of respiratory medicines in practice 3. Advanced drug delivery systems for respiratory diseases 4. Novel drug delivery systems and significance in respiratory diseases 5. Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis 6. Targeting biofilms in chronic respiratory infections using drug delivery systems 7. Absorption enhancement of macromolecule administered intrapulmonary 8. In silico analysis of drug delivery in respiratory disease 9. Concepts of nanotechnology in nanomedicine: From discovery to applications 10. Advancement in translational respiratory research using nanotechnology 11. Nanoparticle-based macromolecule drug delivery to lungs 12. Formulation and role of polymeric and inorganic nanoparticles in respiratory diseases 13. Inhalable hybrid nanocarriers for respiratory disorders 14. Functionalized nanoparticles in pulmonary disease diagnosis 15. Drug delivery system in pulmonary disease: Role of microparticles 16. Microparticulate drug delivery systems for targeting respiratory diseases 17. Porous particulate platforms for enhanced pulmonary delivery of bioactives 18. Liposomes in the treatment of chronic respiratory conditions 19. Theranostic drug delivery systems for targeted therapy of lung diseases 20. Targeted polymeric miceller systems for respiratory diseases 21. Hydrogels for pulmonary drug delivery 22. Mucoadhesive drug delivery systems in respiratory diseases 23. Targeting lung cancer using advanced drug delivery systems 24. Plant-based drug delivery systems in respiratory diseases 25. Role of essential oils in respiratory diseases through advanced and nanodrug delivery systems 26. Pharmacokinetics and pharmacodynamics of the advanced drug delivery systems
A propos de l'auteur
Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the University of Technology Sydney (UTS). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.
Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science,
Sydney, NSW, AustraliaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, AustraliaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, AustraliaLisa G. Pont is a Professor in the Discipline of Pharmacy, Graduate School of Health at the University of Technology Sydney. Pont is a pharmacoepidemiologist with expertise in medicine utilization and health service research to evaluate, understand, and improve the quality and safety of medicine use in practice. Her research explores current practices and patterns of medicines use across populations with a focus on the safety and quality of prescribing and medicines use. Throughout her career, Professor Pont has received a number of awards including two national NPS MedicineWise awards in 2014 and in 2016 for her research. She is a registered pharmacist and was awarded the Society of Hospital Pharmacist of Australia Medal of Merit in 2018.Kylie A. Williams is a pharmacist and academic leader. She is a founding member of the Graduate School of Health at University of Technology Sydney (UTS), where she is currently the Head of Pharmacy and the Deputy Head of School Learning & Teaching. She has over 25 years of academic experience in learning and teaching, curricula development, research, and academic leadership. Professor Williams leads a research team focused on development, implementation, and evaluation of new models of pharmacy and health service delivery. Alongside her research expertise, Professor Williams is internationally recognized for her curriculum development, and has received a number of teaching grants and awards and has coauthored numerous teaching-related peer-reviewed journal articles, professional books, and educational articles for pharmacists.
